BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
2.005
+0.005 (0.25%)
Aug 14, 2025, 11:44 AM - Market open
BeyondSpring Employees
BeyondSpring had 40 employees as of December 31, 2024. The number of employees increased by 4 or 11.11% compared to the previous year.
Employees
40
Change (1Y)
4
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$29,750
Market Cap
80.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 40 | 4 | 11.11% |
| Dec 31, 2023 | 36 | -37 | -50.68% |
| Dec 31, 2022 | 73 | -30 | -29.13% |
| Dec 31, 2021 | 103 | 12 | 13.19% |
| Dec 31, 2020 | 91 | 30 | 49.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BYSI News
- 5 weeks ago - BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure - GlobeNewsWire
- 2 months ago - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewsWire
- 7 months ago - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies - GlobeNewsWire
- 7 months ago - SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - GlobeNewsWire
- 9 months ago - BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting - GlobeNewsWire
- 11 months ago - BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus